Format

Send to

Choose Destination
Sci Rep. 2018 Oct 31;8(1):16129. doi: 10.1038/s41598-018-34229-6.

Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry.

Author information

1
Department of Biofunctional Informatics, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
2
Department of Clinical Laboratory, Medical Hospital, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
3
Department of Cardiovascular Physiology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
4
Heart Rhythm Centre, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
5
Department of Laboratory Molecular Genetics of Haematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
6
Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
7
Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
8
Department of Biofunctional Informatics, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. sasano.bi@tmd.ac.jp.
9
Department of Cardiovascular Physiology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. sasano.bi@tmd.ac.jp.

Abstract

An easy-to-use assessment for activated factor X (FXa) is lacking despite its pivotal role in the coagulation. Dielectric blood coagulometry (DBCM) was recently invented as a novel assessment tool for determining the whole blood coagulability by measuring the temporal change in the permittivity of blood. We previously reported that it could evaluate the global blood coagulability. This study aimed to apply the DBCM for assessing FXa activity and its inhibition by anticoagulants. We performed the DBCM analysis along with measurement of the FXa activity by a fluorometric assay in samples from healthy subjects, and identified a new index named maximum acceleration time (MAT) that had a correlation to the FXa activity. Next the DBCM analysis was performed using blood samples mixed with anticoagulants (unfractionated heparin, dalteparin, and edoxaban). Blood samples with three anticoagulants had different profiles of the temporal change in the permittivity, reflecting their different selectivity for FXa. We compared the MAT with the anti-FXa activity assay, and found that the prolongation of MAT was similarly correlated with the anti-FXa activity regardless of the type of anticoagulants. In conclusion, the DBCM has the possibility for evaluating the innate FXa activity and effect of anticoagulants focusing on their FXa inhibition.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center